Table 2.3.7.3 Open in new tab Results of...

Table 2.3.7.3

Results of a meta-analysis of blinded, randomized, placebo-controlled trials of growth hormone treatment on cardiovascular risk factors in GHD adults

Factors	No of trials	Treatments		Q test	Weighted mean change (GH placebo)
Factors	No of trials	GH	Placebo
Lean mass	19	473	474	ns	2.82 kg (2.68)
Fat Mass	13	352	345	ns	2.82 kg (2.68)	−3.05kg (3.29)
Body mass index	8	134	134	ns	−0.12 kg/m² (1.40)
Triglycerides	11	202	203	ns	0.07mmol/l (0.36)
HDL cholesterol	13	267	261	ns	0.06 mmol/l (0.09)
LDL cholesterol	13	255	248	ns	−0.53 mmol/l (0.29)
Total cholesterol	15	310	306	ns	−0.34 mmol/l (0.31)
Diastolic Blood Pressure	10	200	201	ns	−1.80 mmHg (3.77)
Systolic Blood Pressure	9	190	191	ns	2.06 mmHg (5.34)
Insulin	11	192	194	ns	8.66 pmol/l (6.98)
Glucose	13	254	257	ns	0.22 mmol/l (0.14)

Factors	No of trials	Treatments		Q test	Weighted mean change (GH placebo)
Factors	No of trials	GH	Placebo
Lean mass	19	473	474	ns	2.82 kg (2.68)
Fat Mass	13	352	345	ns	2.82 kg (2.68)	−3.05kg (3.29)
Body mass index	8	134	134	ns	−0.12 kg/m² (1.40)
Triglycerides	11	202	203	ns	0.07mmol/l (0.36)
HDL cholesterol	13	267	261	ns	0.06 mmol/l (0.09)
LDL cholesterol	13	255	248	ns	−0.53 mmol/l (0.29)
Total cholesterol	15	310	306	ns	−0.34 mmol/l (0.31)
Diastolic Blood Pressure	10	200	201	ns	−1.80 mmHg (3.77)
Systolic Blood Pressure	9	190	191	ns	2.06 mmHg (5.34)
Insulin	11	192	194	ns	8.66 pmol/l (6.98)
Glucose	13	254	257	ns	0.22 mmol/l (0.14)

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Adapted with permission, from Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004; 89: 2192–2199.

This Feature Is Available To Subscribers Only